OncoSpherix News & Events
OncoSpherix Relocates to Portal Innovations’ State-of-the-Art Life Sciences Facilities, Poised for Next Stage of Growth
November 20, 2024 OncoSpherix Becomes a Portal Innovations Member Company Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent...
OncoSpherix Showcased at 2024 Georgia Bio Life Sciences Summit, Highlights Latest Advances in Cancer treatment
November 18, 2024 OncoSpherix Participates in Annual Georgia Life Sciences Summit Atlanta, GA – Nov 18, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, proudly participated in...
OncoSpherix expands its operations team with the appointment of Joseph Ellis, Ph.D., as Research Scientist
Oct 1, 2024 Joseph Ellis, Ph.D., joins OncoSpherix’s Research Team Atlanta, GA – Oct 1, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, announces the appointment of Joseph Ellis,...
OncoSpherix Presents at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM.
October 16, 2023 Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation...
OncoSpherix expands leadership team with the appointment of Allan Valmonte, M.B.A., as Vice President of Business Operations
April 28, 2023 Allan Valmonte, M.B.A., former Executive Director, Program Management Office (PMO) at Taysha Gene Therapies, joins OncoSpherix with over 25 years of program/portfolio management and clinical operations experience in the biotechnology and pharmaceutical...
OncoSpherix expands leadership team with the appointment of Steve Coats, Ph.D. as Vice President of Chemistry
April 28, 2023 Dr. Steve Coats, former Senior Director of Chemistry at Cocrystal Pharma, joins OncoSpherix with over 25 years of drug discovery and development experience in biotechnology and large pharmaceutical companies. Atlanta, GA – April 28, 2023 – OncoSpherix,...
OncoSpherix to Present Data from its Hypoxia Inducible Factor (HIF) Inhibitor 64B in Uveal Melanoma
April 12, 2023 64B is a small molecule therapeutic that inhibits the function of hypoxia inducible factors (HIFs) 64B given systemically inhibits primary tumor growth and metastases 64B was far superior to either sunitinib or selumetinib at causing a regression in...
OncoSpherix CEO to Serve as Keynote Speaker at 5th Meridian Drug Discovery Conference in Boston on Tuesday, November 8, 2022
The 5th Meridian Drug Discovery Conference will be held at the Embassy Suites by Hilton at Boston Longan Airport on November 7-8, 2022. Dr. Margaret Offermann will present a keynote address entitled "Mechanism Matters: Overcoming Past Failures in Developing HIF...
OncoSpherix’s CEO Will Give Keynote Presentation Entitled “Overcoming Past Challenges in Developing Safe and Effective Small Molecule Hypoxia Inducible Factor (HIF) Inhibitors for Treatment Of Aggressive Cancers” in San Francisco on Thursday, October 27
The Agile Falcon Drug Discovery Strategic Summit will be held at the Grand Hyatt at the San Francisco Airport on October 27-28, 2022. OncoSpherix's CEO, Dr. Margaret Offermann, will be presenting a keynote address entitled "Overcoming Past Challenges in Developing...
OncoSpherix’s CEO is Keynote Speaker and Moderator at Global Women in STEM Leadership Summit In Atlanta on June 6-7, 2022
The Global Women in STEM Leadership Summit is designed to inspire attendees through sessions tailored specifically for promoting women in STEM. It brings together influential leaders and founders from industry, academia, nonprofit and government to share their...